U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H24N4O6
Molecular Weight 452.4599
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MERIMEPODIB

SMILES

COC1=C(C=CC(NC(=O)NC2=CC=CC(CNC(=O)O[C@H]3CCOC3)=C2)=C1)C4=CN=CO4

InChI

InChIKey=JBPUGFODGPKTDW-SFHVURJKSA-N
InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800008158 http://files.shareholder.com/downloads/VRTX/3251874583x0xS912057-02-12962/875320/filing.pdf https://www.ncbi.nlm.nih.gov/pubmed/23016672

Merimepodib has immunosuppressive activity. It targets hepatitis C indirectly through the inhibition of inositol monophosphate dehydrogenase, which exerts an acute antiproliferative effect on lymphocyte proliferation due to their almost exclusive dependence on the de novo pathway for synthesis of guanosine. Phase II clinical trial study of merimepodib for the treatment of HCV infection and psoriasis were completed. The poor pharmacokinetic-pharmacodynamic results have resulted in discontinuation of clinical trials.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1748 ng/mL
100 mg 3 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3195 ng/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3543 ng × h/mL
100 mg 3 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8210 ng × h/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.
2000 Apr
Novel approaches to the treatment of hepatitis C virus infection.
2000 Mar
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.
2002 May 23
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
2003 Jun 5
Patents

Sample Use Guides

25 or 50 mg every 12h (24 weeks of treatment)
Route of Administration: Oral
The IC50 values for VX-497 in Sprague-Dawley or Lewis rat lymphocytes were similar to the 100 nM human PBMC IC50 values.
Name Type Language
MERIMEPODIB
INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
MERIMEPODIB [USAN]
Common Name English
VX-497
Code English
CARBAMIC ACID, ((3-((((3-METHOXY-4-(5-OXAZOLYL)PHENYL)AMINO)CARBONYL)AMINO)PHENYL)METHYL)-, (3S)-TETRAHYDRO-3-FURANYL ESTER
Common Name English
(S)-TETRAHYDRO-3-FURYL (M-(3-(3-METHOXY-4-(5-OXAZOLYL)PHENYL)UREIDO)BENZYL)CARBAMATE
Systematic Name English
Merimepodib [WHO-DD]
Common Name English
VI-21,497
Code English
merimepodib [INN]
Common Name English
VI-21497
Code English
MERIMEPODIB [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
NCI_THESAURUS C2087
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C66097
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
MERCK INDEX
m7238
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY Merck Index
USAN
MM-03
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
WIKIPEDIA
Merimepodib
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
ChEMBL
CHEMBL304087
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
EPA CompTox
DTXSID70173639
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
CAS
198821-22-6
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
FDA UNII
2ZL2BA06FU
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
EVMPD
SUB34886
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
SMS_ID
100000128133
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
DRUG BANK
DB04862
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
PUBCHEM
153241
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY
INN
8123
Created by admin on Fri Dec 15 16:30:06 GMT 2023 , Edited by admin on Fri Dec 15 16:30:06 GMT 2023
PRIMARY